Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | GPR183 | P32249 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30133833 | 0.90 | MGAM (0.37) | KDM4EJAK2TYK2ALDH1A1ALOX15 | |
| SCHEMBL30133968 | 0.85 | MAPK1 (0.41) | KDM4EJAK2TYK2ALDH1A1ALOX15 | |
| SCHEMBL30133919 | 0.80 | MLYCD (0.33) | JAK2TYK2 | |
| SCHEMBL104460 | 0.76 | KDM4E (0.50) | KDM4EALDH1A1ALOX15HSD17B10GPR183 | |
| SCHEMBL3457728 | 0.76 | KMT2A (0.41) | KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL30134256 | 0.74 | KDM4E (0.55) | KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL1191065 | 0.74 | KDM4E (0.55) | KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL31085152 | 0.71 | HDAC4 (0.49) | KDM4ENPC1RAB9AHDAC4 | |
| SCHEMBL31003073 | 0.66 | NNMT (0.36) | KDM4ENPC1RAB9AHDAC4 | |
| SCHEMBL16044509 | 0.65 | MGAM (0.42) | KDM4EALDH1A1GPR183NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119119033-A | Pyrazolopyridone compounds | 百济神州有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20240300951-A1 | Pyrazolopyridinone Compounds | BEIGENE LTD. (KY) | 2024-09-12 | — | — | US | disclosed |
| US-20240270751-A1 | Pyrazolopyridinone Compounds | BEIGENE LTD. (KY) | 2024-08-15 | — | — | US | disclosed |
| EP-4380936-A1 | PYRAZOLOPYRIDINONE COMPOUNDS | BeiGene, Ltd. (KY) | 2024-06-12 | — | — | EP | disclosed |
| WO-2023011456-A1 | PYRAZOLOPYRIDINONE COMPOUNDS | BEIGENE, LTD. (KY) | 2023-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300951-A1 | Pyrazolopyridinone Compounds | NFATC1, CD4, PBK | KDM4E 2009/4885JAK2 148/4885TYK2 543/4885 |
| US-20240270751-A1 | Pyrazolopyridinone Compounds | NFATC1, CD4, PBK | KDM4E 2009/4885JAK2 148/4885TYK2 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.